Agenus (AGEN) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Agenus (AGEN) has outperformed Zura Bio (ZURA) over the past year, gaining 93.2% versus a loss of 3.6%. Zura Bio is the larger company by market cap ($383.3 million vs $346.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | ZURA |
|---|---|---|
| Share price | $7.67 | $4.00 |
| Market cap | $346.39M | $383.32M |
| 1-day change | +1.72% | -3.15% |
| YTD return | +144.27% | -23.66% |
| 1-year return | +93.20% | -3.61% |
| 5-year return | -92.64% | — |
| P/E ratio (TTM) | 3.03 | — |
| EPS (TTM) | $2.53 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $7.44 |
| 52-week low | $2.71 | $3.15 |
| Distance from 52-week high | -25.61% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.29% | +350.00% |
| Average volume | 4.26M | 1.44M |
| Shares outstanding | 45.16M | 95.83M |
| Employees | 81 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed ZURA by 96.8 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
AGEN vs ZURA FAQ
Which is bigger, Agenus or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $346.39M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or ZURA?
AGEN returned +93.20% over the past 12 months, compared with -3.61% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.